LABELS · bcfd315e-9ade-4659-9f1c-dfb687ba39de

Bendeka

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-01-19
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Full extracted label fields

application numbers

NDA208194

boxed warning exact

brand names

Bendeka

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

generic names

BENDAMUSTINE HYDROCHLORIDE

bcfd315e-9ade-4659-9f1c-dfb687ba39de

indications and usage exact

1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

indications and usage tables exact

is original packager

true

manufacturer names

Teva Pharmaceuticals USA, Inc.

matched search terms

lymphoma
leukemia

package ndcs

63459-348-04

product ndcs

63459-348

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1726097
1726102

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 600
total: 830

terms

https://open.fda.gov/terms/

sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl effective time

20240119

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

substance names

BENDAMUSTINE HYDROCHLORIDE

uniis

981Y8SX18M

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled

Drugs@FDA application source records

application number
NDA208194
payload
all indexed label documents
Appl No
208194
Application Docs Date
2015-12-08 00:00:00
Application Docs ID
19987
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208194s000lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
208194
Application Docs Date
2016-08-02 00:00:00
Application Docs ID
40623
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208194s001s002lbl.pdf
Submission No
1
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2016-06-27 00:00:00
Application Docs ID
40624
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208194s001s002lbl.pdf
Submission No
2
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2017-02-10 00:00:00
Application Docs ID
47169
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208194s005lbl.pdf
Submission No
5
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2018-07-31 00:00:00
Application Docs ID
55065
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208194s013lbl.pdf
Submission No
13
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2019-10-15 00:00:00
Application Docs ID
60572
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208194s019lbl.pdf
Submission No
19
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2019-12-12 00:00:00
Application Docs ID
61244
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208194s020lbl.pdf
Submission No
20
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2021-10-15 00:00:00
Application Docs ID
69000
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208194s024lbl.pdf
Submission No
24
Submission Type
SUPPL
Appl No
208194
Application Docs Date
2024-01-16 00:00:00
Application Docs ID
77228
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208194s026lbl.pdf
Submission No
26
Submission Type
SUPPL
all submission records
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
15
Submission No
1
Submission Status
AP
Submission Status Date
2015-12-07 00:00:00
Submission Type
ORIG
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
1
Submission Status
AP
Submission Status Date
2016-06-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
2
Submission Status
AP
Submission Status Date
2016-06-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
UNKNOWN
Submission Class Code ID
19
Submission No
3
Submission Status
AP
Submission Status Date
2016-09-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
19
Submission No
4
Submission Status
AP
Submission Status Date
2017-02-06 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
5
Submission Status
AP
Submission Status Date
2017-02-09 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
13
Submission Status
AP
Submission Status Date
2018-07-30 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
19
Submission Status
AP
Submission Status Date
2019-10-08 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
20
Submission Status
AP
Submission Status Date
2019-11-08 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
24
Submission Status
AP
Submission Status Date
2021-10-14 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
208194
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
26
Submission Status
AP
Submission Status Date
2024-01-11 00:00:00
Submission Type
SUPPL
Submissions Public Notes
application number
NDA208194
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208194
has approved submission record
true
latest approved submission date
2024-01-11
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
208194
Application Docs Date
2024-01-16 00:00:00
Application Docs ID
77228
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208194s026lbl.pdf
Submission No
26
Submission Type
SUPPL
official application record
Appl No
208194
Appl Public Notes
Appl Type
NDA
Sponsor Name
EAGLE PHARMS
openfda application present
true
products
Active Ingredient
BENDAMUSTINE HYDROCHLORIDE
Appl No
208194
Drug Name
BENDEKA
Form
SOLUTION;INTRAVENOUS
Product No
001
Reference Drug
1
Reference Standard
1
Strength
100MG/4ML (25MG/ML)
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA208194

brand names

Bendeka

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 341
end exclusive: true
exact text: 1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treat
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 0

current approval status

not_reconciled

duplicate text group

dup-8287deba44b89c5b8f29

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-977f0d0f1fe0adf2da10

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

end: 73
end exclusive: true
exact text: is an alkylating drug indicated
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 42

qualifier mentions

context exact
1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL).
kind
biomarker
polarity
not_inferred
span
end
91
end exclusive
true
exact text
alkylating drug indicated for treatment of
label id
bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start
48

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 141
end exclusive: true
exact text: 1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL).
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · limitation of use

application numbers

NDA208194

brand names

Bendeka

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 433
end exclusive: true
exact text: 1 INDICATIONS AND USAGE BENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leuke
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 0

current approval status

not_reconciled

duplicate text group

dup-d036787630f64646617d

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-eb185ca9a4c37848d3fd

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

Source null

qualifier mentions

context exact
Efficacy relative to first line therapies other than chlorambucil has not been established.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
232
end exclusive
true
exact text
first line therapies other than chlorambucil has not been established
label id
bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start
163

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 233
end exclusive: true
exact text: Efficacy relative to first line therapies other than chlorambucil has not been established.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 142

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · unclassified context

application numbers

NDA208194

brand names

Bendeka

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 595
end exclusive: true
exact text: jection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambuci
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 34

current approval status

not_reconciled

duplicate text group

dup-6c884de288fed37d5d50

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-4241cda5321db821a7f8

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 395
end exclusive: true
exact text: ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 234

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA208194

brand names

Bendeka

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 603
end exclusive: true
exact text: hlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has no
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 196

current approval status

not_reconciled

duplicate text group

dup-28ac6c89a39dc3aa7f36

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-dbd166c50101a4405cb1

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 403
end exclusive: true
exact text: ( 1.2 )
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 396

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

NDA208194

brand names

Bendeka

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 730
end exclusive: true
exact text: cil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 204

current approval status

not_reconciled

duplicate text group

dup-a919f1d2a1dfe3ad2c18

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-842ef8378c3f147c5d42

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

end: 465
end exclusive: true
exact text: is indicated
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 453

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 530
end exclusive: true
exact text: 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 404

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · limitation of use

application numbers

NDA208194

brand names

Bendeka

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 822
end exclusive: true
exact text: s of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 331

current approval status

not_reconciled

duplicate text group

dup-d036787630f64646617d

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-0be629e8044d44902a3c

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

Source null

qualifier mentions

context exact
Efficacy relative to first line therapies other than chlorambucil has not been established.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
621
end exclusive
true
exact text
first line therapies other than chlorambucil has not been established
label id
bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start
552

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 622
end exclusive: true
exact text: Efficacy relative to first line therapies other than chlorambucil has not been established.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 531

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 7 · positive indication candidate

application numbers

NDA208194

brand names

Bendeka

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 857
end exclusive: true
exact text: ytic Leukemia (CLL) BENDEKA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 423

current approval status

not_reconciled

duplicate text group

dup-a150fe5e3becfb06ea83

extraction review status

automated_candidate_pending_source_review

generic names

BENDAMUSTINE HYDROCHLORIDE

ind-span-e3da95bd49a2ef63f3b5

label id

bcfd315e-9ade-4659-9f1c-dfb687ba39de

positive predicate support span

end: 674
end exclusive: true
exact text: is indicated
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 662

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 857
end exclusive: true
exact text: 1.2 Non-Hodgkin Lymphoma (NHL) BENDEKA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
label id: bcfd315e-9ade-4659-9f1c-dfb687ba39de
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7b2d9421188bc66c5a81e77e252b152d267f35a942d032c3efad1416a531e729
start: 623

source url

https://api.fda.gov/drug/label.json?search=id%3A%22bcfd315e-9ade-4659-9f1c-dfb687ba39de%22

spl effective date

2024-01-19

spl set id

ace9a43b-f9bd-4896-abfe-0ef4fec67ddf

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice